NCT02300363 - DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Healthy

Interventions

DRUG

Treatment A (rosuvastatin)

10 mg rosuvastatin administered on Day 1 and Day 13

DRUG

Treatment B (LX4211)

400 mg LX4211 administered on Day 7 through Day 13

DRUG

Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)

10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13

Trial Locations (1)

Lexicon Investigational Site, Evansville